Bonyf NV Halts Capital Increase Amid Positive Developments

bonyf NV, a leader in dental consumer goods and dermatological solutions, has decided to cancel its previously planned capital increase due to significant positive business developments. Recent negotiations with strategic partners have opened new commercial opportunities, boosting the company's financial outlook. Additionally, bonyf received a favorable assessment from Dekra Germany for the launch of PerioCream, an innovative product based on proprietary NitrAdine® technology.

PerioCream's market potential was further strengthened by successful clinical studies. This positions bonyf for a faster global rollout, enhancing potential revenue and supporting international growth ambitions. Concurrently, negotiations for FDA registration with a U.S. partner are advancing, marking a key step towards entering the U.S. market. These factors collectively negate the need for a capital increase, placing bonyf in a strong strategic position.